Claims
- 1. A compound of the formula (I): wherein R2 is hydrogen, optionally substituted lower alkyl, or optionally substituted aralkyl;R3 is halogen, hydroxy, lower alkyloxy, or lower alkylthio; n is an integer from 1 to 3; R1 is represented by the formula: whereinR4 is hydrogen, halogen, optionally substituted lower alkyl, lower alkyloxy, lower alkylthio, optionally substituted amino, or nitro; R5 is hydrogen, halogen, optionally substituted lower alkyl, lower alkyloxy, lower alkylthio, optionally substituted amino, nitro, or a non-aromatic heterocyclic group, provided that when R5 is amino substituted with two lower alkyls, R3 is not 6-methyloxy or 5-fluoro; R6 is hydrogen, halogen, optionally substituted lower alkyl, lower alkyloxy, lower alkylthio, optionally substituted amino, or nitro, provided that when R6 is lower alkyl, R3 is not 6-hydroxy or 6-lower alkyloxy; R7 is halogen, optionally substituted lower alkyl, lower alkyloxy, lower alkylthio, optionally substituted amino, or nitro; R8 is hydrogen, halogen, optionally substituted lower alkyl, lower alkyloxy, lower alkylthio, optionally substituted amino, or nitro; and Y is —OH or —NHOH, its optically active substance, its prodrug, its pharmaceutically acceptable salt, or its solvate.
- 2. A compound of claim 1, wherein R1 is a group represented by the formula: wherein R4 is halogen,its optically active substance, its prodrug, its pharmaceutically acceptable salt, or its solvate.
- 3. A compound of claim 1, wherein R1 is a group represented by the formula: wherein R5 is optionally substituted amino or a non-aromatic heterocyclic group,provided that when R5 is amino substituted with two lower alkyls, R3 is not 6-methyloxy or 5-fluoro; its optically active substance, its prodrug, its pharmaceutically acceptable salt, or its solvate.
- 4. A compound of claim 1, wherein R1 is a group represented by the formula: wherein R6 is a lower alkyl,its optically active substance, its prodrug, its pharmaceutically acceptable salt, or its solvate.
- 5. A compound of claim 1, wherein R1 is a group represented by the formula: wherein R7 is lower alkyloxy,its optically active substance, its prodrug, its pharmaceutically acceptable salt, or its solvate.
- 6. A compound of claim 1, wherein R1 is a group represented by the formula: wherein R8 is halogen,its optically active substance, its prodrug, its pharmaceutically acceptable salt, or its solvate.
- 7. A compound of any one of claims 1 to 6, wherein R2 is hydrogen, its optically active substance, its prodrug, its pharmaceutically acceptable salt, or its solvate.
- 8. A compound of any one of claims 1 to 6, wherein R3 is halogen, hydroxy, or lower alkyloxy and n is 1, its optically active substance, its prodrug, its pharmaceutically acceptable salt, or its solvate.
- 9. A pharmaceutical composition containing a compound of any one of claims 1 to 6 as an active ingredient.
- 10. A method for treating a disease related with matrix metalloproteinase of a mammal, which comprises administration to said mammal of a compound of any one of claims 1 to 6 in a pharmaceutically effective amount.
- 11. The compound of claim 1 wherein the non-aromatic heterocyclic group is pyrrolidinyl.
- 12. A compound of the formula (I): wherein R2 is hydrogen, optionally substituted lower alkyl, or optionally substituted aralkyl;R3 is halogen, hydroxy, lower alkyloxy, or lower alkylthio; n is an integer from 1 to 3; R1 is represented by the formula: whereinR4 is hydrogen, halogen, optionally substituted lower alkyl, lower alkyloxy, lower alkylthio, optionally substituted amino, or nitro; R5 is hydrogen, halogen, optionally substituted lower alkyl, lower alkyloxy, lower alkylthio, optionally substituted amino, nitro, provided that when R5 is amino substituted with two lower alkyls, R3 is not 6-methyloxy or 5-fluoro; R6 is hydrogen, halogen, optionally substituted lower alkyl, lower alkyloxy, lower alkylthio, optionally substituted amino, or nitro, provided that when R6 is lower alkyl, R3 is not 6-hydroxy or 6-lower alkyloxy; R7 is halogen, optionally substituted lower alkyl, lower alkyloxy, lower alkylthio, optionally substituted amino, or nitro; R8 is hydrogen, halogen, optionally substituted lower alkyl, lower alkyloxy, lower alkylthio, optionally substituted amino, or nitro; and Y is —OH or —NHOH, its optically active substance, its prodrug, its pharmaceutically acceptable salt, or its solvate.
- 13. A compound of formula A1:its optically active substance, its prodrug, its pharmaceutically acceptable salt, or its solvate.
Priority Claims (1)
Number |
Date |
Country |
Kind |
2000-016370 |
Jan 2000 |
JP |
|
Parent Case Info
This application is the national phase under 35 U.S.C. § 371 of PCT International Application No. PCT/JP01/00412 which has an International tiling date of Jan. 23, 2001, which designated the United States of America.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/JP01/00412 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO01/55133 |
8/2/2001 |
WO |
A |
Foreign Referenced Citations (5)
Number |
Date |
Country |
9727174 |
Jul 1997 |
WO |
994780 |
Feb 1999 |
WO |
200063194 |
Jan 2000 |
WO |
WO 0015213 |
Mar 2000 |
WO |
200015213 |
Mar 2000 |
WO |